Aclaris Therapeutics (ACRS) Competitors $1.90 -0.15 (-7.07%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. VIR, DNA, AVXL, TNGX, ABUS, PVLA, URGN, GYRE, PRME, and IOVAShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Vir Biotechnology (VIR), Ginkgo Bioworks (DNA), Anavex Life Sciences (AVXL), Tango Therapeutics (TNGX), Arbutus Biopharma (ABUS), Palvella Therapeutics (PVLA), Urogen Pharma (URGN), Gyre Therapeutics (GYRE), Prime Medicine (PRME), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Vir Biotechnology Ginkgo Bioworks Anavex Life Sciences Tango Therapeutics Arbutus Biopharma Palvella Therapeutics Urogen Pharma Gyre Therapeutics Prime Medicine Iovance Biotherapeutics Aclaris Therapeutics (NASDAQ:ACRS) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Which has higher earnings and valuation, ACRS or VIR? Aclaris Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M11.02-$132.07M-$1.37-1.39Vir Biotechnology$74.21M10.75-$521.96M-$4.00-1.44 Is ACRS or VIR more profitable? Aclaris Therapeutics has a net margin of -802.03% compared to Vir Biotechnology's net margin of -2,895.94%. Aclaris Therapeutics' return on equity of -34.01% beat Vir Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-802.03% -34.01% -24.18% Vir Biotechnology -2,895.94%-50.22%-40.78% Which has more risk & volatility, ACRS or VIR? Aclaris Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Do analysts prefer ACRS or VIR? Aclaris Therapeutics currently has a consensus price target of $8.71, indicating a potential upside of 357.44%. Vir Biotechnology has a consensus price target of $17.30, indicating a potential upside of 201.13%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Vir Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90Vir Biotechnology 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Do institutionals & insiders believe in ACRS or VIR? 98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 5.6% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 16.0% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to ACRS or VIR? In the previous week, Vir Biotechnology had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 13 mentions for Vir Biotechnology and 11 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.65 beat Vir Biotechnology's score of 0.41 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAclaris Therapeutics beats Vir Biotechnology on 12 of the 17 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$206.37M$2.62B$6.09B$10.48BDividend YieldN/A57.78%5.73%4.78%P/E Ratio-1.3922.8184.2227.04Price / Sales11.02756.43606.15130.16Price / CashN/A175.9337.8662.13Price / Book1.325.2812.306.56Net Income-$132.07M$33.06M$3.32B$276.88M7 Day Performance1.87%-1.31%0.42%0.68%1 Month Performance5.25%9.01%7.68%3.85%1 Year Performance62.82%-4.38%71.71%34.63% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.3908 of 5 stars$1.91-7.1%$8.71+357.4%+76.7%$206.37M$18.72M-1.39100News CoverageAnalyst ForecastAnalyst RevisionGap DownVIRVir Biotechnology3.5317 of 5 stars$5.86+1.0%$17.30+195.2%-26.3%$805.72M$74.21M-1.47580Analyst ForecastInsider TradeDNAGinkgo Bioworks1.2358 of 5 stars$13.20-2.4%$9.00-31.8%+82.4%$800.38M$230.82M-2.25640AVXLAnavex Life Sciences3.4549 of 5 stars$8.62-7.0%$44.00+410.4%+63.1%$796.24MN/A-15.1240TNGXTango Therapeutics1.4891 of 5 stars$8.47+18.6%$10.50+24.0%+28.4%$794.40M$42.07M-6.3790ABUSArbutus Biopharma1.8347 of 5 stars$4.28+4.1%$5.00+16.8%+7.4%$787.88M$6.17M-14.7690News CoveragePVLAPalvella Therapeutics1.7575 of 5 stars$76.22+9.0%$75.50-0.9%N/A$773.07M$42.81M-6.30N/AShort Interest ↑URGNUrogen Pharma3.9868 of 5 stars$16.76+0.5%$32.00+90.9%+34.4%$771.69M$90.40M-5.05200Positive NewsGYREGyre Therapeutics1.283 of 5 stars$8.39+5.4%$17.00+102.6%-37.5%$766.65M$105.76M839.8440News CoveragePRMEPrime Medicine0.5106 of 5 stars$5.65-0.5%N/AN/A$764.38M$2.98M-3.62N/AGap DownIOVAIovance Biotherapeutics4.2749 of 5 stars$2.14+1.9%$11.90+456.1%-76.1%$759.89M$164.07M-1.74500Gap Down Related Companies and Tools Related Companies Vir Biotechnology Competitors Ginkgo Bioworks Competitors Anavex Life Sciences Competitors Tango Therapeutics Competitors Arbutus Biopharma Competitors Palvella Therapeutics Competitors Urogen Pharma Competitors Gyre Therapeutics Competitors Prime Medicine Competitors Iovance Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
